{Reference Type}: Case Reports
{Title}: Expanding the genetic and clinical characteristics of Protocadherin 19 gene mutations.
{Author}: Dell'Isola GB;Mencaroni E;Fattorusso A;Tascini G;Prontera P;Imperatore V;Di Cara G;Striano P;Verrotti A;
{Journal}: BMC Med Genomics
{Volume}: 15
{Issue}: 1
{Year}: 08 2022 17
{Factor}: 3.622
{DOI}: 10.1186/s12920-022-01313-w
{Abstract}: PCDH19-related epilepsy is a rare X-linked type of epilepsy caused by genomic variants of the Protocadherin 19 (PCDH19) gene. The clinical characteristics of PCDH19-related epilepsy are epileptic and non-epileptic symptoms with highly variable severity among patients.
We present a case of a 4-year old female with PCDH19-related epilepsycaused by new variants in the PCDH19 gene. Our patient was admitted for the first time at the age of 12 months for seizure clusters arising under condition of apyrexia. The electroencephalography (EEG) showed frontal paroxysmal activity. The genetic analysis identified the two variants c.1006G > A (p.Val336Met) and c.1014C > A (p.Asp338Glu) in the gene PCDH19. The patient was treated with Carbamazepine and Clonazepam achieving the disappearance of seizures. During the follow-up, the neurological examination was persistently normal with neither cognitive impairment nor behavior disturbances. From 2 years of age EEG controls were persistently normal.
This patient presents two novel variants of the PCDH19 gene associated with a mild form of epilepsy with normal cognitive development with an apparently better prognosis. According to our experience, the dual therapy with Carbamazepine and Clonazepam has led to a good control of seizures.